MAPK3 and cardiomyopathy: This blockade strategy offers promising therapeutic targeting in dystrophin-deficient cardiomyopathy [47] as, in cardiac fibroblasts, AngII was further found to increase periostin expression via Ras/p38 MAPK/CREB and ERK1/2/Tgf-β1 pathways [48].